1. Home
  2. NERV vs HUMA Comparison

NERV vs HUMA Comparison

Compare NERV & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$4.51

Market Cap

301.6M

Sector

Health Care

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.06

Market Cap

308.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NERV
HUMA
Founded
2007
2004
Country
United States
United States
Employees
N/A
184
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.6M
308.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
NERV
HUMA
Price
$4.51
$1.06
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$10.50
$6.19
AVG Volume (30 Days)
120.8K
7.6M
Earning Date
05-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$41,175,600.00
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
N/A
$248.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$0.55
52 Week High
$12.46
$2.84

Technical Indicators

Market Signals
Indicator
NERV
HUMA
Relative Strength Index (RSI) 36.18 45.35
Support Level $4.30 $0.89
Resistance Level $4.59 $1.28
Average True Range (ATR) 0.37 0.13
MACD 0.01 -0.03
Stochastic Oscillator 13.70 12.38

Price Performance

Historical Comparison
NERV
HUMA

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: